Literature DB >> 9853191

The effects of norepinephrine on myocardial biology: implications for the therapy of heart failure.

W S Colucci1.   

Abstract

Increased sympathetic nervous system (SNS) activity in patients with heart failure may help to support cardiovascular function. However, increased SNS activity, particularly if prolonged, may exert deleterious effects on cardiovascular structure and function by stimulating pathologic myocardial remodeling. In vitro, norepinephrine mimics many features of myocardial remodeling, including hypertrophy of individual myocytes and reinduction of fetal genes. Furthermore, stimulation of the beta-adrenergic pathway has been shown to stimulate apoptosis of cardiac myocytes in vitro, in rats infused with isoproterenol, and in mice that overexpress the stimulatory G-protein, Gs. Thus, increased SNS activity, acting via beta-adrenergic receptors, may play an important role in the progression of myocardial failure by acting directly on myocytes and other cell types in the heart to regulate fundamental biologic properties such as growth, apoptosis, and the composition of the extracellular matrix. This thesis provides a mechanism by which beta-adrenergic antagonists may inhibit or reverse pathologic remodeling, improve myocardial structure and function, and prolong patient survival.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9853191      PMCID: PMC6655544          DOI: 10.1002/clc.4960211305

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  13 in total

Review 1.  Clinical safety of blood flow-restricted training? A comprehensive review of altered muscle metaboreflex in cardiovascular disease during ischemic exercise.

Authors:  Michelle Cristina-Oliveira; Kamila Meireles; Marty D Spranger; Donal S O'Leary; Hamilton Roschel; Tiago Peçanha
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-11-08       Impact factor: 4.733

2.  Phosphoinositide kinases play key roles in norepinephrine- and angiotensin II-induced increase in phosphatidylinositol 4,5-bisphosphate and modulation of cardiac function.

Authors:  Jia-Xi Xu; Man Si; Hui-Ran Zhang; Xing-Juan Chen; Xi-Dong Zhang; Chuan Wang; Xiao-Na Du; Hai-Lin Zhang
Journal:  J Biol Chem       Date:  2014-01-21       Impact factor: 5.157

Review 3.  The crosstalk between autonomic nervous system and blood vessels.

Authors:  Yulan Sheng; Li Zhu
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-03-10

4.  Fibroblast growth factor 23 and sudden versus non-sudden cardiac death: the Cardiovascular Health Study.

Authors:  Rajat Deo; Ronit Katz; Ian H de Boer; Nona Sotoodehnia; Bryan Kestenbaum; Kenneth J Mukamal; Michel Chonchol; Mark J Sarnak; David Siscovick; Michael G Shlipak; Joachim H Ix
Journal:  Am J Kidney Dis       Date:  2015-01-05       Impact factor: 8.860

Review 5.  Cardiometabolic-based chronic disease: adiposity and dysglycemia drivers of heart failure.

Authors:  Eduardo Thadeu de Oliveira Correia; Jeffrey I Mechanick; Letícia Mara Dos Santos Barbetta; Antonio José Lagoeiro Jorge; Evandro Tinoco Mesquita
Journal:  Heart Fail Rev       Date:  2022-04-04       Impact factor: 4.214

6.  The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress.

Authors:  René R Wenzel; Anna Mitchell; Winfried Siffert; Sandra Bührmann; Thomas Philipp; Rafael F Schäfers
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

Review 7.  Sympathetic Activation in Chronic Heart Failure: Potential Benefits of Interventional Therapies.

Authors:  Kamila Lachowska; Marcin Gruchała; Krzysztof Narkiewicz; Dagmara Hering
Journal:  Curr Hypertens Rep       Date:  2016-07       Impact factor: 5.369

8.  Perspectives of bilateral thoracic sympathectomy for treatment of heart failure.

Authors:  Raphael Dos Santos Coutinho E Silva; Fernando Luiz Zanoni; Rafael Simas; Luiz Felipe Pinho Moreira
Journal:  Clinics (Sao Paulo)       Date:  2021-08-04       Impact factor: 2.365

Review 9.  Effects of beta-blockers on neurohormonal activation in patients with congestive heart failure.

Authors:  D Baran; E M Horn; K Hryniewicz; S D Katz
Journal:  Drugs       Date:  2000-11       Impact factor: 11.431

Review 10.  Advances in the pathogenesis of cardiorenal syndrome type 3.

Authors:  Anna Clementi; Grazia Maria Virzì; Alessandra Brocca; Massimo de Cal; Silvia Pastori; Maurizio Clementi; Antonio Granata; Giorgio Vescovo; Claudio Ronco
Journal:  Oxid Med Cell Longev       Date:  2015-03-04       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.